Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial.
James, N Spears, M Dearnaley, D Mason, M Parker, C Ritchie, A Russell, J Schiavone, F Attard, G
James, N
Spears, M
Dearnaley, D
Mason, M
Parker, C
Ritchie, A
Russell, J
Schiavone, F
Attard, G
Citations
Altmetric:
Abstract
The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. Furthermore, no clinical trial has assessed the role of RT in patients with node-positive (N+) M0 disease. The STAMPEDE Trial includes such individuals, allowing an exploratory multivariate analysis of the impact of radical RT.
Description
Date
2015-11-25
Publisher
Collections
Keywords
Type
Article
Citation
Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. 2015:1-10 JAMA Oncol